ID | 61864 |
FullText URL | |
Author |
Miyawaki, Yoshia
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Shimizu, Sayaka
Institute for Health Outcome & Process Evaluation Research (i-Hope International)
Ogawa, Yusuke
Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University
Sada, Ken-Ei
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Katayama, Yukitoshi
Ushimado Marine Institute, Faculty of Science, Okayama University
Kaken ID
researchmap
Asano, Yosuke
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Hayashi, Keigo
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamamura, Yuriko
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
Hiramatsu-Asano, Sumie
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ohashi, Keiji
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Morishita, Michiko
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Haruki
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Takano-Narazaki, Mariko
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Matsumoto, Yoshinori
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
researchmap
Yajima, Nobuyuki
Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University
Yoshimi, Ryusuke
Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
Shimojima, Yasuhiro
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
Ohno, Shigeru
Center for Rheumatic Diseases, Yokohama City University Medical Center
Kajiyama, Hiroshi
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
Ichinose, Kunihiro
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
Sato, Shuzo
Department of Rheumatology, Fukushima Medical University School of Medicine
Fujiwara, Michio
Department of Rheumatology, Yokohama Rosai Hospital
Yamazaki, Hajime
Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University
Yamamoto, Yosuke
Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University
Wada, Jun
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Fukuhara, Shunichi
Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University
|
Abstract | Background While survival of systemic lupus erythematosus (SLE) patients has improved substantially, problems remain in the management of their emotional health. Medium to high-dose glucocorticoid doses are known to worsen emotional health; the effect is unclear among patients receiving relatively low-dose glucocorticoids. This study aims to investigate the association between low glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS). Methods This cross-sectional study drew on data from SLE patients in 10 Japanese institutions. The participants were adult patients with SLE duration of >= 1 year who met LLDAS criteria at the study visit from April 2018 through September 2019. The exposure was the daily glucocorticoid dose (mg oral prednisolone). The outcome was the emotional health score of the lupus patient-reported outcome scale (range: 0 to 100). Multiple linear regression analysis was performed with adjustment for confounders including disease-related damage, activity, and psychotropic drug use. Results Of 192 patients enrolled, 175 were included in the analysis. Their characteristics were as follows: female, 89.7%; median age, 47 years (interquartile range (IQR): 37.0, 61.0). Median glucocorticoid dose was 4.0 mg (IQR 2.0, 5.0), and median emotional health score 79.2 (IQR 58.3, 91.7). Multiple linear regression analysis showed daily glucocorticoid doses to be associated with worse emotional health (beta coefficient = - 2.54 [95% confidence interval - 4.48 to - 0.60], P = 0.01). Conclusions Daily glucocorticoid doses were inversely associated with emotional health among SLE patients in LLDAS. Further studies are needed to determine whether glucocorticoid tapering leads to clinically significant improvements in emotional health.
|
Keywords | Systemic lupus erythematosus
Glucocorticoid
Emotional health
Patient-reported outcome
Depression
Anxiety
Cross-sectional study
|
Published Date | 2021-03-10
|
Publication Title |
Arthritis Research & Therapy
|
Volume | volume23
|
Issue | issue1
|
Publisher | BMC
|
ISSN | 1478-6354
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © The Author(s). 2021
|
File Version | publisher
|
PubMed ID | |
NAID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1186/s13075-021-02466-2
|
License | http://creativecommons.org/licenses/by/4.0/
|